StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$14.05−1.72 (-10.91%)

Close on Nov 18, 2026Market cap $34.92MP/E –Yield –

Scribe Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.92M–
Q2 FY2025Jun 30, 2025$4.90M–

More Scribe Therapeutics figures

See a number that looks wrong?